Chinook Therapeutics Raises $105 Million for Kidney Disease Therapies

Edward Kim | Equities.com | May 25, 2022

The company is in Phase 3 trials with atrasentan for IgA nephropathy (IgAN).

Bausch + Lomb Raises $630 Million in IPO, Missing Expectations

Edward Kim | Equities.com | May 06, 2022

The stock was priced at $18 per share, off a filing range of $21 - $24.

Aeglea BioTherapeutics Raises $45 Million Via Registered Direct Offering

Edward Kim | Equities.com | May 05, 2022

The company is waiting on FDA review of its lead product candidate.

Arizona Sonoran Copper Raises C$35 Million, Including Strategic Investment by Rio Tinto

Edward Kim | Equities.com | Apr 28, 2022

Rio Tinto takes 7.2% stake.

BioXcel Therapeutics Inks $260 Million Strategic Financing With Oaktree and Qatar Investment Authority

Edward Kim | Equities.com | Apr 20, 2022

The financing will support the commercialization of BioXcel's recently approved Igalmi sublingual film for agitation associated with schizophrenia or bipolar I or II disorder.

Blue Water Vaccines Raises $8 Million in Private Placement After Stock Plummets

Edward Kim | Equities.com | Apr 14, 2022

After trading near $70 a month ago, the stock is now down below its IPO price.

Affimed Raises $90 Million in Follow-on Equity Offering

Edward Kim | Equities.com | Apr 13, 2022

Image source: Affimed

Affimed (AFMD) announced 22,500,000 of its common shares at a public offering price of $4.00

 

 

 

Investment thesis

 

_____

Source: Equities News

...

Selecta Biosciences Raises $39 Million in Stock + Warrants Deal

Edward Kim | Equities.com | Apr 08, 2022

Each share of common stock offered is accompanied by a warrant to buy 0.75 shares.

Trevi Therapeutics Raises $55 Million in Private Placement

Edward Kim | Equities.com | Apr 08, 2022

The deal comprises stock at $1.90 plus pre-funded warrants.

SELLAS Life Sciences Down Sharply After Raising $25 Million

Edward Kim | Equities.com | Apr 01, 2022

The deal was priced at $5.40, a 19% discount to Thursday's close.